アロプリノール:ヒトにおけるピリミジン代謝の変化

W N Kelley, T D Beardmore

Science (New York, N.Y.)

|July 24, 1970

まとめ

アロプリノールは,オロチジンとオロチ酸の分泌を増やすことにより,ピリミジン代謝に顕著な影響を及ぼします. これは,アルロプリノールの代謝産物がピリミジン合成における重要な酵素を阻害するからである.

科学分野:

バイオケミストリーバイオケミストリー
薬理学薬理学とは
メタボリック経路は

背景:

アロプリノールは主に尿酸合成を阻害することが知られている.
そのより広範な代謝効果はあまり理解されていない.
ピリミジンの代謝は,細胞の機能において重要な役割を果たします.

研究の目的:

ピリミジン代謝に対するアルロプリノールの効果を調査する.
観察された代謝変化の根底にある特定のメカニズムを特定する.

主な方法:

尿による排泄産物 (オロチジン,オロ酸) の分析.
ヒトの赤血球オロチジル性デカルボキシラーゼを用いたインビトロ酵素分析.
アロピュリノールの代謝産物 (アロピュリノールリボヌクレオチド,クサントシン5'-モノフォスファート) の特定.

主要な成果:

アロプリノール治療は,尿中のオロチジンとオロチ酸の有意な増加をもたらしました.
アロピュリノールリボヌクレオチドとクサントシン5'-モノフォスファートは,オロチディル性デカルボキシラーゼの強力な阻害剤として特定されました.
これらの発見は,ピリミジン合成経路に直接的な影響を及ぼすことを示唆しています.

結論:

アロプリノールは,尿酸に対する既知の効果を超えて,ピリミジン代謝を大幅に変化させます.
アロプリノールの代謝産物によるオロチドリルデカルボキシラーゼの抑制は,ピリミジンの前駆体分泌の増加の可能性のあるメカニズムである.
これらの代謝変化の臨床的影響を理解するために,さらなる研究が必要である.

さらに関連する動画

04:36

Strategies to Enhance Cultivation of Anaerobic Bacteria from Gastrointestinal Tract of Chicken

Published on: May 10, 2024

08:32

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture

Published on: March 20, 2026

関連する概念動画

01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

01:22

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...

01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

関連する実験動画